Splash Beverage (SBEV) 10-Q 14 Aug 19 2019 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2019	Aug. 15, 2019
Document And Entity Information
Entity Registrant Name	CANFIELD MEDICAL SUPPLY, INC.
Entity Central Index Key	0001553788
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Is Entity's Reporting Status Current?	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	true
Entity Small Business	true
Entity Ex Transition Period	true
Entity Shell Company	false
Entity Interactive Data Current	Yes
Entity File Number	000-55114
Entity Incorporation, State or Country Code	CO
Entity Common Stock, Shares Outstanding		11,813,200
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2019

CONDENSED BALANCE SHEETS (UNAUD

CONDENSED BALANCE SHEETS (UNAUDITED) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Current Assets
Cash	$ 235,324	$ 6,980
Accounts receivable, net	205,565	300,993
Inventory	36,572	41,695
Total Current Assets	477,461	349,668
Other Assets
Right-of-use asset	31,198	0
Equipment, net of accumulated depreciation of $94,145 and $92,907	44,393	58,627
Total Other Assets	75,591	58,627
Total Assets	553,052	408,295
Current Liabilities
Accounts payable and accrued liabilities	235,264	331,034
Line of credit	74,463	66,181
Due to officer	267,878	0
Current portion of long-term debt	4,491	8,241
Total Current Liabilities	582,096	405,456
Long-term Liabilities
Lease liability	31,198	0
Long-term debt	3,797	5,498
Total Long-term Liabilities	34,995	5,498
Total Liabilities	617,091	410,954
Stockholders' Equity (Deficit)
Preferred stock, no par value; 5,000,000 shares authorized; no shares issued and outstanding	0	0
Common stock, no par value; 100,000,000 shares authorized; 11,813,200 and 11,477,200 shares issued and outstanding	345,515	245,515
Accumulated deficit	(409,554)	(248,174)
Total Stockholders' Equity (Deficit)	(64,039)	(2,659)
Total Liabilities and Stockholders' Equity (Deficit)	$ 553,052	$ 408,295

CONDENSED BALANCE SHEETS (Paren

CONDENSED BALANCE SHEETS (Parenthetical) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Preferred stock, no par value	$ 0	$ 0
Preferred stock, authorized shares	5,000,000	5,000,000
Preferred stock, issued shares	0	0
Preferred stock, outstanding shares	0	0
Common stock, no par value	$ 0	$ 0
Common stock, authorized shares	100,000,000	100,000,000
Common stock, issued shares	11,813,200	11,477,200
Common stock, outstanding shares	11,813,200	11,477,200
Accumulated depreciation	$ 94,145	$ 92,907

CONDENSED STATEMENTS OF OPERATI

CONDENSED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Income Statement [Abstract]
Sales (net of returns)	$ 174,947	$ 354,765	$ 446,902	$ 699,389
Cost of goods sold	117,351	147,035	249,746	317,211
Gross profit	57,596	207,730	197,156	382,178
Operating expenses:
Salaries and wages	92,919	75,393	181,740	147,160
Professional fees	15,181	8,665	50,536	39,930
Depreciation	14,520	17,742	25,730	30,375
Other selling, general and administrative	39,448	37,449	91,700	80,279
Total operating expenses	162,068	139,249	349,706	297,744
Income (loss) from operations	(104,472)	68,481	(152,550)	84,434
Other income (expense):
Interest income	32	0	32	0
Interest expense	(2,798)	(1,250)	(4,140)	(2,444)
Gain (Loss) on sale of fixed assets	194	477	(4,722)	5,726
Total other income (expense)	(2,572)	(773)	(8,830)	3,282
Income (loss) before provision for income taxes	(107,044)	67,708	(161,380)	87,716
Provision for income tax	0	0	0	0
Net income (loss)	$ (107,044)	$ 67,708	$ (161,380)	$ 87,716
Net income (loss) per share (basic and fully diluted)	$ (0.01)	$ 0.01	$ (0.01)	$ 0.01
Weighted average number of common shares outstanding	11,514,123	11,277,200	11,495,764	11,277,200

CONDENSED STATEMENTS OF STOCKHO

CONDENSED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)	Common Stock	Accumulated Deficit	Total
Beginning Balance at Dec. 31, 2017	$ 243,515	$ (316,380)	$ (72,865)
Beginning Balance, in Shares at Dec. 31, 2017	11,277,200
Net income (loss) for the period		20,008	20,008
Ending Balance at Mar. 31, 2018	$ 243,515	(296,372)	(52,857)
Ending Balance, in Shares at Mar. 31, 2018	11,277,200
Beginning Balance at Dec. 31, 2017	$ 243,515	(316,380)	(72,865)
Beginning Balance, in Shares at Dec. 31, 2017	11,277,200
Net income (loss) for the period			87,716
Ending Balance at Jun. 30, 2018	$ 243,515	(228,664)	14,851
Ending Balance, in Shares at Jun. 30, 2018	11,277,200
Beginning Balance at Mar. 31, 2018	$ 243,515	(296,372)	(52,857)
Beginning Balance, in Shares at Mar. 31, 2018	11,277,200
Net income (loss) for the period		67,708	67,708
Ending Balance at Jun. 30, 2018	$ 243,515	(228,664)	14,851
Ending Balance, in Shares at Jun. 30, 2018	11,277,200
Beginning Balance at Dec. 31, 2018	$ 245,515	(248,174)	(2,659)
Beginning Balance, in Shares at Dec. 31, 2018	11,477,200
Net income (loss) for the period		(54,336)	(54,336)
Ending Balance at Mar. 31, 2019	$ 245,515	(302,510)	(56,995)
Ending Balance, in Shares at Mar. 31, 2019	11,477,200
Beginning Balance at Dec. 31, 2018	$ 245,515	(248,174)	(2,659)
Beginning Balance, in Shares at Dec. 31, 2018	11,477,200
Sales of common stock			100,000
Net income (loss) for the period			(161,380)
Ending Balance at Jun. 30, 2019	$ 345,515	(409,554)	(64,039)
Ending Balance, in Shares at Jun. 30, 2019	11,813,200
Beginning Balance at Mar. 31, 2019	$ 245,515	(302,510)	(56,995)
Beginning Balance, in Shares at Mar. 31, 2019	11,477,200
Sales of common stock	$ 100,000		100,000
Sales of common stock, in Shares	336,000
Net income (loss) for the period		(107,044)	(107,044)
Ending Balance at Jun. 30, 2019	$ 345,515	$ (409,554)	$ (64,039)
Ending Balance, in Shares at Jun. 30, 2019	11,813,200

CONDENSED STATEMENTS OF CASH FL

CONDENSED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Cash Flows From Operating Activities:
Net income (loss)	$ (161,380)	$ 87,716
Adjustments to reconcile net income (loss) to net cash provided by (used for) operating activities:
(Gain) loss on disposal of fixed assets	4,722	(5,726)
Depreciation	25,730	30,375
Bad debt expense	15,101	0
Changes in operating assets and liabilities:
(Increase) decrease in accounts receivable	80,327	(75,088)
(Increase) decrease in inventory	5,123	(9,489)
Increase (decrease) in accounts payable and accrued liabilities	(95,770)	15,724
Net cash provided by (used for) operating activities	(126,147)	43,512
Cash Flows From Investing Activities:
Proceeds from sale of fixed assets	1,706	6,474
Purchases of fixed assets	(17,924)	(25,358)
Net cash (used for) investing activities	(16,218)	(18,884)
Cash Flows From Financing Activities:
Net proceeds from (payments on) line of credit	8,282	(3,650)
Proceeds received from officer	267,878	0
Payments on long-term debt	(5,451)	(5,601)
Proceeds from sales of common stock	100,000	0
Net cash provided by (used for) financing activities	370,709	(9,251)
Net Increase (Decrease) in Cash	228,344	15,377
Cash At The Beginning Of The Period	6,980	17,921
Cash At The End Of The Period	235,324	33,298
Schedule Of Non-Cash Investing And Financing Activities
Recording of lease liability and right-of-use asset	43,677	0
Amortization of right-of-use asset	12,479	0
Supplemental Disclosure
Cash paid for interest	4,140	2,444
Cash paid for income taxes	$ 0	$ 0

ORGANIZATION, OPERATIONS AND SU

ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	NOTE 1. ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Canfield Medical Supply, Inc. (the “Company”), was incorporated in the State of Ohio on September 3, 1992, and changed domicile to Colorado on April 18, 2012. The Company is in the business of home health services, primarily the selling of durable medical equipment and medical supplies to the public, nursing homes, hospitals and other end users. Effective June 21, 2019 WesBev LLC, a Nevada limited liability company ("WesBev"), acquired 8,000,000 shares of common stock from Michael J. West, a founder, director and former principal shareholder of the Company, consisting of approximately 69.7% of the issued and outstanding shares of the Company at the time of the purchase. As part of his agreement with WesBev, Mr. West undertook to appoint or cause the appointment of up to three persons nominated by WesBev to the board of directors of the Company. Effective June 21, 2019 the Company sold 336,000 shares of common stock to WesBev for $100,000. Following these stock purchases WesBev beneficially owns 8,336,000 shares, or approximately 71% of the issued and outstanding shares of the Company and may be deemed to be in control of the registrant. The accompanying financial statements have been prepared by the Company without audit. In the opinion of management, all adjustments (which include only normal recurring adjustments) necessary to present fairly the financial position, results of operations and cash flows for the six months ended June 30, 2019 and 2018 have been made. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted. It is suggested that these financial statements be read in conjunction with the financial statements and notes thereto included in the Company’s December 31, 2018 audited financial statements. The results of operations for the periods ended June 30, 2019 and 2018 are not necessarily indicative of the operating results for the full year. Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash and cash equivalents The Company considers all highly liquid investments with an original maturity of three months or less as cash equivalents. Accounts receivable The majority of the Company’s revenues are received from Medicare, Medicaid, and private insurance companies. As such, the Company records revenues at allowable amounts, net of estimated allowances and discounts based on contracted prices and historical collection rates. The Company reviews accounts receivable periodically for collectability and establishes an allowance for doubtful accounts and records bad debt expense when deemed necessary. The Company wrote off bad debts of $15,101 and $0 for the six months ended June 30, 2018 and 2017, respectively. At June 30, 2019 and December 31, 2018, the Company has determined that no allowance for doubtful accounts is necessary. Property and equipment Property and equipment are recorded at cost and depreciated under straight line methods over each item's estimated useful life. Inventory The Company carries inventory of durable medical equipment and medical supplies for resale. Inventory is accounted for on a first–in first-out basis. Revenue recognition It is the Company’s policy that revenues from product sales is recognized in accordance with ASC 606 "Revenue Recognition." Five basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that creates enforceable rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to the performance obligations in the contract, which requires the company to allocate the transaction price to each performance obligation on the basis of the relative standalone selling prices of each distinct good or services promised in the contract; and (5) Recognizing revenue when (or as) the entity satisfies a performance obligation by transferring a promised good or service to a customer. The amount of revenue recognized is the amount allocated to the satisfied performance obligation. For sales of our Company products, a purchase arrangement is evidenced by a written order, with delivery considered as made after physical customer acceptance. Although rare, defective products may be returned, with other return issues considered on a case by case basis. Services such as periodic scheduled deliveries are contracted in writing, and generally billed monthly. Any service revenue earned by the Company for services such as safety and set up consulting or claims processing is recorded after the service is performed. Rental of durable home medical equipment is evidenced by written contract, with revenue recognized when rent is earned. Advertising costs Advertising costs are expensed as incurred. The Company had advertising costs during the six months ended June 30, 2019 and 2018 of $1,047 and $8,637, respectively. Income tax The Company accounts for income taxes pursuant to ASC 740. Under ASC 740, deferred taxes are provided for using the liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment. Net income (loss) per share The net income (loss) per share is computed by dividing the net income (loss) by the weighted average number of shares of common outstanding. Warrants, stock options, and common stock issuable upon the conversion of the Company's convertible debt or preferred stock (if any), are not included in the computation if the effect would be anti-dilutive and would increase the earnings or decrease loss per share. There were no potentially dilutive debt or equity instruments issued or outstanding during the six months ended June 30, 2019 or 2018. Financial Instruments The carrying value of the Company’s financial instruments, as reported in the accompanying balance sheets, approximates fair value. Concentrations Financial instruments that potentially subject the Company to concentrations of credit risk include cash and cash equivalents. The Company places its cash and cash equivalents at well-known financial institutions, where at times, such balances may exceed FDIC insurance limits. The Company receives a significant amount of its revenues in reimbursements from Medicare and Medicaid thru competitive bidding processes. There is no guarantee that the Company will be selected as a winning contract supplier under future bidding rounds. Long-Lived Assets In accordance with ASC 350, the Company regularly reviews the carrying value of intangible and other long-lived assets for the existence of facts or circumstances, both internally and externally, that suggest impairment. If impairment testing indicates a lack of recoverability, an impairment loss is recognized by the Company if the carrying amount of a long-lived asset exceeds its fair value. Products and services, geographic areas and major customers The Company’s business of medical supply sales constitutes one operating segment. All revenues each year were domestic and to external customers. Leases In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, “Lease (Topic 842),”

EQUIPMENT

EQUIPMENT	6 Months Ended
	Jun. 30, 2019
Property, Plant and Equipment [Abstract]
EQUIPMENT	NOTE 2. EQUIPMENT Fixed assets are comprised of office equipment, vehicles, and the wheelchair and hospital bed rental pool, which consists of wheelchairs and hospital beds rented to customers over the shorter of the 13-month rental period mandated by Medicaid and Medicare, or the period over which the customer requires use of the wheelchair or hospital bed. At the end of the use period, the wheelchair or hospital bed is transferred to the customer. Depreciation is computed over the estimated useful life of the assets, ranging from 13 months to 7 years, on the straight-line basis. Depreciation expense for the six months ended June 30, 2019 and 2018 was $25,730 and $30,375, respectively. Accumulated depreciation totaled $94,145 and $92,907 at June 30, 2019 and December 31, 2018, respectively.

LINE OF CREDIT

LINE OF CREDIT	6 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
LINE OF CREDIT	NOTE 3. LINE OF CREDIT At June 30, 2019 and December 31, 2018, the Company owed a bank $74,463 and $66,181, respectively, under a revolving line of credit. The line of credit is secured by all Company assets, is capped at $100,000, is due on demand, and bears interest at variable rates approximating 7% on average . Interest expense under the note totaled $2,798 and $4,140 during the six months ended June 30, 2019 and 2018, respectively. During the six months ended June 30, 2019 and 2018, the Company made net (borrowings) and principal payments of ($8,282) and $3,650, respectively.

LONG-TERM DEBT

LONG-TERM DEBT	6 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
LONG-TERM DEBT	NOTE 4. LONG-TERM DEBT Long-term debt consists of the following vehicle loans, which are collateralized by their underlying vehicles with net carrying values exceeding the outstanding loan amounts : June 30, 2019 December 31, 2018 3.53% installment note payable $352 monthly, including interest, through July 2019 $ 702 $ 2,782 3.79% installment note payable $299 monthly, including interest, through July 2021 6,890 8,532 2.99% installment note payable $350 monthly, including interest, through August 2019 696 2,425 Total 8,288 13,739 Less principal due within one year (4,491 ) (8,241 ) TOTAL LONG-TERM DEBT $ 3,797 $ 5,498

COMMON STOCK

COMMON STOCK	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
COMMON STOCK	NOTE 5. COMMON STOCK In June 2019, the Company received net proceeds of $100,000 from the sale of 336,000 shares of no-par value common stock at $0.298 per share.

LEASE COMMITMENTS

LEASE COMMITMENTS	6 Months Ended
	Jun. 30, 2019
Leases [Abstract]
LEASE COMMITMENTS	NOTE 6. LEASE COMMITMENTS The Company rents office space under a non-cancellable lease through September 2020 with monthly payments of approximately $2,292. Pursuant to ASC 842, an operating lease right-of-use (“ROU”) asset and liability were recognized at January 1, 2019 based on the present value of lease payments over the remaining lease term. The ROU asset represents the Company’s right to use the underlying office space asset for the lease term, and the lease liability represents the Company’s obligation to make lease payments arising from the lease. Generally, the implicit rate of interest in arrangements is not readily determinable and the Company utilizes its incremental borrowing rate in determining the present value of lease payments. The operating lease ROU asset includes any lease payments made and excludes lease incentives. The Company recognized $13,800 in lease expense during the six months ended June 30, 2019. Remaining lease term at June 30, 2019 (in years) 1.2 Discount rate 5 % Six Months Ended June 30, 2019 Operating lease expense $ 13,800 Cash paid for amounts included in measurement of lease liability $ 13,800 The supplemental balance sheet information related to leases for the period is as follows: Right-of-Use Asset ROU Asset, January 1, 2019 $ 43,677 Amortization of ROU Asset (12,479 ) ROU Asset, June 30, 2019 $ 31,198 Maturities of the Company’s lease liabilities are as follows: Year Ending Payments 2019 $ 13,752 2020 20,628 Total lease payments 34,380 Less: Imputed interest/present value discount (3,182 ) Present value of lease liability at June 30, 2019 $ 31,198

GOING CONCERN

GOING CONCERN	6 Months Ended
	Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	NOTE 7. GOING CONCERN The Company has suffered losses from operations and has working capital and stockholders’ equity deficits. In all likelihood, the Company will be required to make significant future expenditures in connection with marketing efforts along with general administrative expenses. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The Company may raise additional capital through the sale of its equity securities, through an offering of debt securities, or through borrowings from financial institutions or related parties. By doing so, the Company hopes to generate sufficient capital to execute its business plan of selling medical supplies on an ongoing basis. Management believes that actions presently being taken to obtain additional funding provide the opportunity for the Company to continue as a going concern.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2019
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 8. SUBSEQUENT EVENTS The Company has evaluated subsequent events through the date these financial statements were issued and determined that there are no reportable subsequent events.

ORGANIZATION, OPERATIONS AND _2

ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2019
Accounting Policies [Abstract]
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Cash and cash equivalents	Cash and cash equivalents The Company considers all highly liquid investments with an original maturity of three months or less as cash equivalents.
Accounts receivable	Accounts receivable The majority of the Company’s revenues are received from Medicare, Medicaid, and private insurance companies. As such, the Company records revenues at allowable amounts, net of estimated allowances and discounts based on contracted prices and historical collection rates. The Company reviews accounts receivable periodically for collectability and establishes an allowance for doubtful accounts and records bad debt expense when deemed necessary. The Company wrote off bad debts of $15,101 and $0 for the six months ended June 30, 2018 and 2017, respectively. At June 30, 2019 and December 31, 2018, the Company has determined that no allowance for doubtful accounts is necessary.
Property and equipment	Property and equipment Property and equipment are recorded at cost and depreciated under straight line methods over each item's estimated useful life.
Inventory	Inventory The Company carries inventory of durable medical equipment and medical supplies for resale. Inventory is accounted for on a first–in first-out basis.
Revenue recognition	Revenue recognition It is the Company’s policy that revenues from product sales is recognized in accordance with ASC 606 "Revenue Recognition." Five basic steps must be followed before revenue can be recognized; (1) Identifying the contract(s) with a customer that creates enforceable rights and obligations; (2) Identifying the performance obligations in the contract, such as promising to transfer goods or services to a customer; (3) Determining the transaction price, meaning the amount of consideration in a contract to which an entity expects to be entitled in exchange for transferring promised goods or services to a customer; (4) Allocating the transaction price to the performance obligations in the contract, which requires the company to allocate the transaction price to each performance obligation on the basis of the relative standalone selling prices of each distinct good or services promised in the contract; and (5) Recognizing revenue when (or as) the entity satisfies a performance obligation by transferring a promised good or service to a customer. The amount of revenue recognized is the amount allocated to the satisfied performance obligation. For sales of our Company products, a purchase arrangement is evidenced by a written order, with delivery considered as made after physical customer acceptance. Although rare, defective products may be returned, with other return issues considered on a case by case basis. Services such as periodic scheduled deliveries are contracted in writing, and generally billed monthly. Any service revenue earned by the Company for services such as safety and set up consulting or claims processing is recorded after the service is performed. Rental of durable home medical equipment is evidenced by written contract, with revenue recognized when rent is earned.
Advertising costs	Advertising costs Advertising costs are expensed as incurred. The Company had advertising costs during the six months ended June 30, 2019 and 2018 of $1,047 and $8,637, respectively.
Income tax	Income tax The Company accounts for income taxes pursuant to ASC 740. Under ASC 740, deferred taxes are provided for using the liability method whereby deferred tax assets are recognized for deductible temporary differences and operating loss carryforwards and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.
Net income (loss) per share	Net income (loss) per share The net income (loss) per share is computed by dividing the net income (loss) by the weighted average number of shares of common outstanding. Warrants, stock options, and common stock issuable upon the conversion of the Company's convertible debt or preferred stock (if any), are not included in the computation if the effect would be anti-dilutive and would increase the earnings or decrease loss per share. There were no potentially dilutive debt or equity instruments issued or outstanding during the six months ended June 30, 2019 or 2018.
Financial Instruments	Financial Instruments The carrying value of the Company’s financial instruments, as reported in the accompanying balance sheets, approximates fair value.
Concentrations	Concentrations Financial instruments that potentially subject the Company to concentrations of credit risk include cash and cash equivalents. The Company places its cash and cash equivalents at well-known financial institutions, where at times, such balances may exceed FDIC insurance limits. The Company receives a significant amount of its revenues in reimbursements from Medicare and Medicaid thru competitive bidding processes. There is no guarantee that the Company will be selected as a winning contract supplier under future bidding rounds.
Long-Lived Assets	Long-Lived Assets In accordance with ASC 350, the Company regularly reviews the carrying value of intangible and other long-lived assets for the existence of facts or circumstances, both internally and externally, that suggest impairment. If impairment testing indicates a lack of recoverability, an impairment loss is recognized by the Company if the carrying amount of a long-lived asset exceeds its fair value.
Products and services, geographic areas and major customers	Products and services, geographic areas and major customers The Company’s business of medical supply sales constitutes one operating segment. All revenues each year were domestic and to external customers.
Leases	Leases In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, “Lease (Topic 842),”

LONG-TERM DEBT (Tables)

LONG-TERM DEBT (Tables)	6 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
Schedule of Long Term Debt	Long-term debt consists of the following vehicle loans, which are collateralized by their underlying vehicles with net carrying values exceeding the outstanding loan amounts : June 30, 2019 December 31, 2018 3.53% installment note payable $352 monthly, including interest, through July 2019 $ 702 $ 2,782 3.79% installment note payable $299 monthly, including interest, through July 2021 6,890 8,532 2.99% installment note payable $350 monthly, including interest, through August 2019 696 2,425 Total 8,288 13,739 Less principal due within one year (4,491 ) (8,241 ) TOTAL LONG-TERM DEBT $ 3,797 $ 5,498

LEASE COMMITMENTS (Tables)

LEASE COMMITMENTS (Tables)	6 Months Ended
	Jun. 30, 2019
Leases [Abstract]
Components of lease expense and supplemental information related to lease	The Company recognized $13,800 in lease expense during the six months ended June 30, 2019. Remaining lease term at June 30, 2019 (in years) 1.2 Discount rate 5 % Six Months Ended June 30, 2019 Operating lease expense $ 13,800 Cash paid for amounts included in measurement of lease liability $ 13,800
Supplemental balance sheet information related to leases	The supplemental balance sheet information related to leases for the period is as follows: Right-of-Use Asset ROU Asset, January 1, 2019 $ 43,677 Amortization of ROU Asset (12,479 ) ROU Asset, June 30, 2019 $ 31,198
Maturities of lease liabilities	Maturities of the Company’s lease liabilities are as follows: Year Ending Payments 2019 $ 13,752 2020 20,628 Total lease payments 34,380 Less: Imputed interest/present value discount (3,182 ) Present value of lease liability at June 30, 2019 $ 31,198

ORGANIZATION, OPERATIONS AND _3

ORGANIZATION, OPERATIONS AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Accounting Policies [Abstract]
Advertising cost	$ 1,047	$ 8,637
Allowance for doubtful accounts	$ 0		$ 0
Potentially dilutive shares	0	0
Bad debt expense	$ 15,101	$ 0

EQUIPMENT (Details Narrative)

EQUIPMENT (Details Narrative) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Depreciation	$ 14,520	$ 17,742	$ 25,730	$ 30,375
Accumulated depreciation	$ 94,145		$ 94,145		$ 92,907
Minimum [Member]
Estimated useful life of assets			13 months
Maximum [Member]
Estimated useful life of assets			7 years

LINE OF CREDIT (Details Narrati

LINE OF CREDIT (Details Narrative) - USD ($)	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Debt Disclosure [Abstract]
Line of credit	$ 74,463		$ 66,181
Secured line of credit	100,000
Interest expense	2,798	$ 4,140
Repayments of Lines of Credit	$ (8,282)	$ (3,650)

LONG-TERM DEBT (Details)

LONG-TERM DEBT (Details) - USD ($)	Jun. 30, 2019	Dec. 31, 2018
Long Term Gross	$ 8,288	$ 13,739
Less principal due within one year	(4,491)	(8,241)
Total Long Term debt	3,797	5,498
Long-term Debt One [Member]
Note Payable, monthly installment	352
Long Term Gross	702	2,782
Long-term Debt Two [Member]
Note Payable, monthly installment	299
Long Term Gross	6,890	8,532
Long-term Debt Three [Member]
Note Payable, monthly installment	350
Long Term Gross	$ 696	$ 2,425

COMMON STOCK (Details Narrative

COMMON STOCK (Details Narrative)	3 Months Ended	6 Months Ended
	Jun. 30, 2019USD ($)$ / shares	Jun. 30, 2019USD ($)$ / sharesshares
Equity [Abstract]
Proceeds from sales of common stock | $	$ 100,000	$ 100,000
Number of shares sold for proceeds | shares		336,000
Value of common stock sold (per share) | $ / shares	$ 0.298	$ 0.298

LEASE COMMITMENTS (Details)

LEASE COMMITMENTS (Details)	6 Months Ended
	Jun. 30, 2019USD ($)
Leases [Abstract]
Remaining lease term (in years)	1 year 2 months 12 days
Discount rate	5.00%
Operating lease expense	$ 13,800
Cash paid for amounts included in measurement of lease liability	$ 13,800

LEASE COMMITMENTS (Details 1)

LEASE COMMITMENTS (Details 1)	6 Months Ended
	Jun. 30, 2019USD ($)
Right-of-Use Asset
ROU Asset, at beginning	$ 43,677
Amortization of ROU Asset	(12,479)
ROU Asset, at end	$ 31,198

LEASE COMMITMENTS (Details 2)

LEASE COMMITMENTS (Details 2)	Jun. 30, 2019USD ($)
Leases [Abstract]
2019	$ 13,752
2020	20,628
Total lease payments	34,380
Less: Imputed interest/present value discount	(3,182)
Present value of lease liability	$ 31,198

LEASE COMMITMENTS (Details Narr

LEASE COMMITMENTS (Details Narrative)	6 Months Ended
	Jun. 30, 2019USD ($)
Leases [Abstract]
Office space approximate monthly payment	$ 2,292
Lease expense	$ 13,800